ArticleEXCLI journal2026
Can nitric oxide-responsive polymers enable precision therapeutics for ageing?
Article in EXCLI journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disruptions in nitric oxide homeostasis, characterised by endothelial dysfunction, neurodegeneration, metabolic decline, and chronic inflammation represent a hallmark of the ageing process. These pathological features led to the development of NO-responsive polymeric systems which exploit the endogenous gasotransmitter fluctuations for offering therapeutic and diagnostic applications. This commentary highlights the advances in NO-responsive polymers, which undergo NO-triggered self-assembly or disassembly, fluorescence activation for intracellular NO imaging, NO scavenging, and site-specific drug release. Although critical challenges still persist, including tissue-specific variability in NO levels and validation in clinically relevant ageing models, the contemporary advances in polymer engineering and design aim to translate these intelligent biomaterials towards ageing-targeted precision therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.